Meiji to separate out pharma ops in major restructuring
This article was originally published in Scrip
The diversified Japanese group Meiji Holdings is to separate out its pharmaceutical operations next year as part of a wider restructuring aimed at increasing the flexibility and independence of its various businesses.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.